trial · primary record
BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)
Colorectal Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 220 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Incidence and severity of adverse events ([S]AEs) |
| Registry ID | NCT04421820 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:03.845Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04421820
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.